Renal angina

Can a vitamin treat COVID-19-related acute kidney injury?

Retrieved on: 
Monday, August 2, 2021
Kidney diseases, Medical specialties, Organs anatomy), Anatomy, Acute kidney injury, Kidney disease, Kidney, Renal angina, Kidney ischemia

The randomized study will test the safety of nicotinamide riboside in hospitalized COVID-19 patients and if a biomarker relevant to acute kidney injury will be improved with the study treatment.

Key Points: 
  • The randomized study will test the safety of nicotinamide riboside in hospitalized COVID-19 patients and if a biomarker relevant to acute kidney injury will be improved with the study treatment.
  • "The potential benefit for patients enrolled in this study would be less kidney injury and preservation of kidney function," Dr. Sharma said.
  • "Our goal is to reduce the severity of acute kidney disease in patients with COVID-19 and potentially other types of acute kidney disease."
  • Acute kidney injury, which is reversible, is sudden loss of kidney function.

Acute Kidney Injury (AKI) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Kidney diseases, Medical emergencies, Acute kidney injury, Organ failure, Aki, Branches of biology, Renal angina

The "Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Kidney Injury (AKI) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Acute Kidney Injury - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), And Japan.
  • The mortality adjusted incident population of AKI in hospitalized patients in the seven major market, was estimated to be 6,544,569 in 2020.
  • In the United States, mortality adjusted incident population of AKI in hospitalized patients accounted for 2,231,147 in 2020.

Global Acute Kidney Injury (AKI) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Health, General Health, Kidney diseases, Organ failure, Acute kidney injury, Aki, Branches of biology, Renal angina

The "Acute Kidney Injury (AKI) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute Kidney Injury (AKI) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Acute Kidney Injury (AKI) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology as well as the AKI market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Kidney Injury?
  • Out of the above-mentioned countries, which country would have the highest incident population of Acute Kidney Injury during the forecast period (2021-2030)?

2021 Insights on the Acute Pain Industry - Key Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
General Health, Pharmaceutical, Health, Branches of biology, Nervous system, Pain, Acute pain, Nociception, Suffering, Disease, Renal angina, Neck pain

The "Global Acute Pain Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Pain Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The research report, Global Acute Pain Epidemiology and Patient Flow Analysis - 2021, provides Acute Pain epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Acute Pain patients, history of the disease at the population level (Acute Pain prevalence, Acute Pain incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Acute Pain patients by age group, gender
    The data from this research will help executives:
    Establish basis for Acute Pain market sizing, assessing market potential, and developing drug forecast models
    Identify Acute Pain patients segments through age groups, gender, and disease sub-types
    Evaluate Acute Pain market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005703/en/

Global Renal Fibrosis Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, General Health, Kidney diseases, Cystic fibrosis, Renal angina

b'The "Global Renal Fibrosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Renal Fibrosis Epidemiology and Patient Flow Analysis - 2021, provides Renal Fibrosis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Renal Fibrosis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Renal Fibrosis Epidemiology and Patient Flow Analysis - 2021, provides Renal Fibrosis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Renal Fibrosis patients, history of the disease at the population level (Renal Fibrosis prevalence, Renal Fibrosis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Renal Fibrosis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Renal Fibrosis market sizing, assessing market potential, and developing drug forecast models\nIdentify Renal Fibrosis patients segments through age groups, gender, and disease sub-types\nEvaluate Renal Fibrosis market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005194/en/\n'

Lyfaquin®, a resuscitative agent marketed in India, restores renal blood flow and protects tissue damage after hemorrhagic shock-induced acute kidney injury (AKI)

Retrieved on: 
Monday, May 3, 2021
Medical specialties, Kidney diseases, Clinical medicine, Medicine, Aviation medicine, Diving medicine, Hypoxia, Oxygen, Pulmonology, Ischemia, Renal angina, Kidney ischemia

The Company is marketing Centhaquine Citrate, with the brand name Lyfaquinto health care professionals in India.\nPharmazz is pleased to announce the peer-reviewed publication of the manuscript titled "Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia."

Key Points: 
  • The Company is marketing Centhaquine Citrate, with the brand name Lyfaquinto health care professionals in India.\nPharmazz is pleased to announce the peer-reviewed publication of the manuscript titled "Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia."
  • Lyfaquin increased renal blood flow, augmented hypoxia response, decreased tissue damage, and apoptosis following hemorrhagic shock-induced acutekidneyinjury (AKI) in the rat.\nAKI has significantly increased in the past couple of decades.
  • The etiology of AKI may be multifactorial and is substantially associated with increased morbidity and mortality.
  • Except as required by applicable law, Pharmazz, Inc. does not intend to update any forward-looking statements to conform these statements to actual results.\n'

Dascena Announces Publication of Results From Its Machine Learning Algorithm for Prediction of Acute Kidney Injury in Kidney International Reports

Retrieved on: 
Tuesday, March 16, 2021
Technology, Research, Medical devices, FDA, Software, Biotechnology, Other Health, Health, Science, Kidney diseases, Medical specialties, Cybernetics, Learning, Machine learning, Acute kidney injury, Articles, Medicine, Renal angina, MELD-Plus, Previse, Dascena

Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced the publication in Kidney International Reports of results from a study evaluating the companys machine learning algorithm, PreviseTM, for the earlier prediction of acute kidney injury (AKI).

Key Points: 
  • Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced the publication in Kidney International Reports of results from a study evaluating the companys machine learning algorithm, PreviseTM, for the earlier prediction of acute kidney injury (AKI).
  • Previse has previously received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
  • These findings with Previse are exciting and further demonstrate the role we believe machine learning algorithms can play in disease prediction.
  • Dascena is developing machine learning diagnostic algorithms to enable early disease intervention and improve care outcomes for patients.

Acute Kidney Injury Found in Children with COVID-19 and MIS-C

Retrieved on: 
Monday, March 8, 2021
Biotechnology, Health, Consumer, Other Health, Pharmaceutical, Other Science, Research, Managed care, Infectious diseases, Children, General Health, Hospitals, Science, Clinical trials, Medical specialties, Anatomy, Medicine, Organ failure, Kidney diseases, Nephrology, Multisystem inflammatory syndrome in children, Kidney failure, Aki, Acute kidney injury, Kidney, Renal angina

A team of investigators at the Feinstein Institutes for Medical Research and Northwells Division of Pediatric Nephrology recently published new research in the journal Kidney International which showed 11.8 percent of admitted children with COVID-19 and MIS-C developed acute kidney injury (AKI).

Key Points: 
  • A team of investigators at the Feinstein Institutes for Medical Research and Northwells Division of Pediatric Nephrology recently published new research in the journal Kidney International which showed 11.8 percent of admitted children with COVID-19 and MIS-C developed acute kidney injury (AKI).
  • View the full release here: https://www.businesswire.com/news/home/20210308005578/en/
    Christine Sethna, MD and Abby Basalely, MD published a study linking children with COVID-19 and MIS-C to kidney injury.
  • AKI is a sudden episode of kidney failure or damage, preventing waste from being filtered within the body.
  • It is important for doctors on the frontlines and those caring for these children after discharge to understand the connection between kidney injury and COVID-19 or MIS-C.

Neovasc Comments on Journal of the American Heart Association Publication

Retrieved on: 
Friday, February 5, 2021
Acute pain, Angina, Cardiology, Renal angina, Canadian Cardiovascular Society grading of angina pectoris

VANCOUVER and MINNEAPOLIS, Feb. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc , Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that the Journal of the American Heart Association has published an article entitled, Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina .

Key Points: 
  • VANCOUVER and MINNEAPOLIS, Feb. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc , Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) today announced that the Journal of the American Heart Association has published an article entitled, Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina .
  • The prestigious journal is the official publication of the American Heart Association, and the article offers important insights into the burden of angina on both patients and healthcare systems.
  • The retrospective analysis of veterans in the United States utilized natural language processing to identify over 14,000 patients suffering from angina.
  • The study found that patients suffering from angina had worse outcomes and higher rates of healthcare utilization than patients without angina.

End Stage Renal Disease Market Size Worth $193.8 Billion By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, January 27, 2021
Kidney diseases, Anatomy, Nephrology, Organ failure, Branches of biology, Artificial kidney, Membrane technology, Kidney failure, Chronic kidney disease, Kidney, Autosomal dominant polycystic kidney disease, Renal angina

SAN FRANCISCO, Jan. 27, 2021 /PRNewswire/ -- The global end stage renal disease market size is anticipated to reach USD 193.8 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 27, 2021 /PRNewswire/ -- The global end stage renal disease market size is anticipated to reach USD 193.8 billion by 2028, according to a new report by Grand View Research, Inc.
  • The increasing number of patients suffering from end stage renal disease (also known as kidney failure) and the rising prevalence of hypertension and diabetes are fueling the market growth.
  • Technological advancements including the innovation of wearable artificial kidney (WAK) in the treatment of renal failure are expediting the overall market growth.
  • Grand View Research has segmented the global end stage renal disease market on the basis of treatment and region:
    End-Stage Renal Disease Treatment Outlook (Revenue, USD Million, 2016 - 2028)